174 related articles for article (PubMed ID: 19078166)
1. Role of Parathyroid Hormone Related Peptide (PTHrP) in Hypercalcemia of Malignancy and the Development of Osteolytic Metastases.
de Vernejoul MC
J Clin Rheumatol; 1997 Apr; 3(2 Suppl):109. PubMed ID: 19078166
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.
Chirgwin JM; Guise TA
Crit Rev Eukaryot Gene Expr; 2000; 10(2):159-78. PubMed ID: 11186331
[TBL] [Abstract][Full Text] [Related]
3. [PTHrP and breast cancer].
Devys A; Lortholary A; Audran M
Bull Cancer; 2001 Nov; 88(11):1075-80. PubMed ID: 11741801
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of osteolytic bone metastases.
Guise TA
Cancer; 2000 Jun; 88(12 Suppl):2892-8. PubMed ID: 10898330
[TBL] [Abstract][Full Text] [Related]
5. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.
Clines GA; Guise TA
Endocr Relat Cancer; 2005 Sep; 12(3):549-83. PubMed ID: 16172192
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.
Guise TA; Yin JJ; Taylor SD; Kumagai Y; Dallas M; Boyce BF; Yoneda T; Mundy GR
J Clin Invest; 1996 Oct; 98(7):1544-9. PubMed ID: 8833902
[TBL] [Abstract][Full Text] [Related]
7. Hypercalcemia of malignancy--new insights into an old syndrome.
Esbrit P
Clin Lab; 2001; 47(1-2):67-71. PubMed ID: 11214225
[TBL] [Abstract][Full Text] [Related]
8. [Hypercalcemia of malignancy: clinical features, diagnosis and treatment].
Farias ML
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):816-24. PubMed ID: 16444366
[TBL] [Abstract][Full Text] [Related]
9. Oral cinacalcet responsiveness in non-parathyroid hormone mediated hypercalcemia of malignancy.
Sheehan MT; Wermers RA; Jatoi A; Loprinzi CL; Onitilo AA
Med Hypotheses; 2020 Oct; 143():110149. PubMed ID: 32763659
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo.
Uy HL; Mundy GR; Boyce BF; Story BM; Dunstan CR; Yin JJ; Roodman GD; Guise TA
Cancer Res; 1997 Aug; 57(15):3194-9. PubMed ID: 9242449
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of osteolytic bone metastases in breast carcinoma.
Käkönen SM; Mundy GR
Cancer; 2003 Feb; 97(3 Suppl):834-9. PubMed ID: 12548583
[TBL] [Abstract][Full Text] [Related]
12. Hypercalcemia in breast cancer.
Francini G; Petrioli R; Maioli E; Gonnelli S; Marsili S; Aquino A; Bruni S
Clin Exp Metastasis; 1993 Sep; 11(5):359-67. PubMed ID: 8375111
[TBL] [Abstract][Full Text] [Related]
13. Malignant hypercalcemia.
Basso U; Maruzzo M; Roma A; Camozzi V; Luisetto G; Lumachi F
Curr Med Chem; 2011; 18(23):3462-7. PubMed ID: 21756237
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone-related protein and bone metastases.
Guise TA
Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of the spectrum of skeletal complications of neoplasia.
Goltzman D; Karaplis AC; Kremer R; Rabbani SA
Cancer; 2000 Jun; 88(12 Suppl):2903-8. PubMed ID: 10898332
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms and treatment of hypercalcemia of malignancy.
Clines GA
Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
[TBL] [Abstract][Full Text] [Related]
17. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Mundy GR; Yoneda T; Hiraga T
Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
[TBL] [Abstract][Full Text] [Related]
18. Effects of calcium-sensing receptor on the secretion of parathyroid hormone-related peptide and its impact on humoral hypercalcemia of malignancy.
Chattopadhyay N
Am J Physiol Endocrinol Metab; 2006 May; 290(5):E761-70. PubMed ID: 16603723
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy.
Firkin F; Schneider H; Grill V
Leuk Lymphoma; 1998 May; 29(5-6):499-506. PubMed ID: 9643563
[TBL] [Abstract][Full Text] [Related]
20. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
